FDA panel urges Acrotech to speed up study on cancer drugs
16 Nov 2023 //
REUTERS
Evive enters agreement with Acrotech Biopharma to commercialize Ryzneuta in US
24 Nov 2022 //
INDIANPHARMAPOST
FDA`s ODAC to review accelerated approvals for multiple myeloma, leukemia
24 Sep 2021 //
ENDPTS
Acrotech Announces the Publication of Data From a Phase 1 Study of BELEODAQ®
26 Apr 2021 //
BUSINESSWIRE
Acrotech Announces the Publication of Data From a Phase 1 Study of BELEODAQ®
26 Apr 2021 //
BUSINESSWIRE